Randall Carpenter, M.D.
Chief Scientific Officer
Dr. Carpenter’s career experience includes providing primary care to underserved populations, performing clinical and basic science research, and leadership positions in academic medicine, pharmaceutical and biotechnology companies. Most recently, he founded Seaside Therapeutics to leverage breakthrough scientific discoveries and develop therapeutics capable of correcting molecular perturbations that increase vulnerability to intellectual disability and autism. The experiences and knowledge he gained are directly relevant to his role at RSRT. For example, experience establishing collaborations with expert clinicians, academic medical centers, scientists, patient advocacy groups, NIH, Merck and Roche provide insights for effectively leveraging the expertise of a wide range of stakeholders.
He also authored and served as principal investigator on UO1 translational medicine grants jointly funded by NIMH, NINDS, NICHD, Autism Speaks and FRAXA, helped establish a fragile X clinical trial network, participated in NIH/FDA workgroups, and directly engaged FDA to define regulatory requirements for development of drugs to treat fragile X syndrome. He continues to be engaged in parallel and complimentary efforts through participation in the advisory boards of EU-AIMS and the Translational Neuroscience Center of Boston Children’s Hospital and as a Research Affiliate in the Department of Brain and Cognitive Sciences at MIT.
Prior to Seaside Therapeutics, Dr. Carpenter served as President and CEO of Sention, VP of Clinical Research & Development and Regulatory Affairs at Adolor Corporation and member of Astra Pain Control’s Global Therapeutic Area Team. While in industry, he led translational medicine teams responsible for 8 successful IND submissions and dozens of FDA-compliant clinical trials. Prior to joining industry, he held academic faculty appointments at Virginia Mason Medical Center, the University of Washington and Wake Forest University where he specialized in anesthesiology, pain management and translational medicine.
I am thrilled to join RSRT during this auspicious moment in time, and look forward to rapidly facilitating progress.Randall Carpenter | February 2016